# Phase 1 Multiple Sclerosis trials recruiting: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 1 for Multiple Sclerosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Multiple Sclerosis trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/multiple-sclerosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07935031 | A Study of IMS001 in Patients With Multiple Sclerosis | Zhuhai Hengqin ImStem Biotechnology Co., Ltd. | Phase 1 | Recruiting | Multiple Sclerosis | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935031) |
| August 24, 2026 | NCT07783269 | A Basket Study of CTA313 in Participants With Active Autoimmune Diseases | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS), Autoimmune Encephalitis | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783269) |
| June 30, 2026 | NCT07676266 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | The Affiliated Hospital of Qingdao University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676266) |
| May 26, 2026 | NCT07606521 | A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus | Polpharma Biologics International AG | Phase 1 | Not yet recruiting | Multiple Sclerosis | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07606521) |
| May 14, 2026 | NCT07587125 | Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis | Xijing Hospital | Phase 1 | Recruiting | Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587125) |
| May 1, 2026 | NCT07562074 | Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis | University of Calgary | Phase 1 | Not yet recruiting | Multiple Sclerosis, Depression - Major Depressive Disorder, Fatigue | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562074) |
| April 13, 2026 | NCT07526493 | Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological... | Tongji Hospital | Phase 1 | Recruiting | Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526493) |
| April 13, 2026 | NCT07523100 | A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis. | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523100) |
| January 14, 2026 | NCT07341828 | A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy | Huashan Hospital | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341828) |
| December 26, 2025 | NCT07304154 | Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment | Kite, A Gilead Company | Phase 1 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304154) |
| December 8, 2025 | NCT07270120 | Senolytics for Secondary Progressive MS | Ohio State University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS) Secondary Progressive | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270120) |
| November 4, 2025 | NCT07224373 | An Open-label Study of AZD0120 in Adults With Multiple Sclerosis | AstraZeneca | Phase 1 | Recruiting | Multiple Sclerosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224373) |
| October 28, 2025 | NCT07221799 | OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis | University of Maryland, Baltimore | Phase 1 | Not yet recruiting | Multiple Sclerosis, Neuropathic Pain | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221799) |
| August 24, 2025 | NCT07139743 | Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | Autolus Limited | Phase 1 | Recruiting | Progressive Multiple Sclerosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139743) |
| July 25, 2025 | NCT07085676 | Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases | Sponsor not shown (see the record) | Phase 1 | Recruiting | Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085676) |
| May 31, 2025 | NCT06999434 | Exploring the Utility of \[18F\]3F4AP for Demyelination Imaging | Yale University | Phase 1 | Recruiting | Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06999434) |
| March 28, 2025 | NCT06900192 | A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis | Orca Biosystems, Inc. | Phase 1 | Not yet recruiting | Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06900192) |
| November 8, 2024 | NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | TG Therapeutics, Inc. | Phase 1 | Recruiting | B-cell Mediated Autoimmune Disorders | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06680037) |
| September 19, 2024 | NCT06592703 | Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis | Rennes University Hospital | Phase 1 | Recruiting | Multiple Sclerosis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06592703) |
| February 8, 2024 | NCT06249438 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | RenJi Hospital | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06249438) |
| November 18, 2023 | NCT06138132 | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple... | Stanford University | Phase 1 | Recruiting | Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06138132) |
| May 9, 2023 | NCT05849467 | Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | Recruiting | Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05849467) |
| April 27, 2023 | NCT05832515 | AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis | St. Petersburg State Pavlov Medical University | Phase 1 | Recruiting | Multiple Sclerosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05832515) |
| November 17, 2022 | NCT05620940 | A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects. | Inventage Lab., Inc. | Phase 1 | Recruiting | Opioid Dependence, Alcohol Dependence, Multiple Sclerosis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05620940) |
| September 14, 2022 | NCT05539729 | Vancomycin Study in Multiple Sclerosis (MS) | Icahn School of Medicine at Mount Sinai | Phase 1 | Recruiting | Multiple Sclerosis | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05539729) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| St. Petersburg State Pavlov Medical University | 1 |
| Xijing Hospital | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Queen Mary University of London | 1 |
| University of Calgary | 1 |
| Rennes University Hospital | 1 |
| Autolus Limited | 1 |
| National Cancer Institute (NCI) | 1 |
| Stanford University | 1 |
| The Foundation for Orthopaedics and Regenerative Medicine | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Tongji Hospital | 1 |
| Yale University | 1 |
| University of Alabama at Birmingham | 1 |
| Huashan Hospital | 1 |
| RenJi Hospital | 1 |
| Polpharma Biologics International AG | 1 |
| Zhuhai Hengqin ImStem Biotechnology Co., Ltd. | 1 |
| [Kite, A Gilead Company](https://specstream.ai/data/clinical-trials/company/kite-a-gilead-company) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [TG Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/tg-therapeutics-inc) | 1 |
| Orca Biosystems, Inc. | 1 |
| Massachusetts General Hospital | 1 |
| Ohio State University | 1 |
| The Affiliated Hospital of Qingdao University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 6 |
| Canada | 5 |
| United Kingdom | 3 |
| Australia | 3 |
| France | 2 |
| Russia | 1 |
| Israel | 1 |
| Spain | 1 |
| Greece | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fish and chips restaurants in the United States](https://specstream.ai/data/businesses/fish-and-chips-restaurants/united-states)
- [Moving companies in the United States](https://specstream.ai/data/businesses/moving-companies/united-states)
- [Surgery practices in the United States](https://specstream.ai/data/businesses/surgery-practices/united-states)
- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
